Scanning electron micrograph of an HIV-infected cell. Credit: NIAID/Flickr.

ViiV Healthcare has reported positive results from the Phase III BRIGHTE clinical trial of fostemsavir evaluated for heavily treatment-experienced (HTE) patients with HIV-1 infection.

Fostemsavir is a HIV-1 attachment inhibitor being developed to bind to gp120 for preventing viral attachment to CD4.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Subjects given fostemsavir in combination with a failing regimen were observed to achieve a greater decrease in HIV-1 viral load after one week of treatment when compared to placebo.

Following the treatment, all patients were administered with fostemsavir and an optimised background regimen, which demonstrated virologic suppression in 54% of participants at 24 weeks.

The randomised and non-randomised Phase III trial assessed the safety and efficacy of fostemsavir in 371 patients with documented resistance, intolerability and/or contraindication to all antiretroviral (ARV) agents in a minimum of four out of the six available ARV classes.

“Patients who participated in this study had very limited treatment options left upon entry into the study.”

ViiV Healthcare chief scientific and medical officer John Pottage said: “Patients who participated in this study were failing their current antiretroviral regimens and had very limited treatment options left upon entry into the study, and the addition of fostemsavir to their failing regimen resulted in meaningful reductions in viral load at one week.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

BRIGHTE’s primary endpoint was mean change in log10 HIV-1 RNA between day one and day eight for the randomised arm, while the key secondary endpoints included durability of response at weeks 24, 48 and 96, safety and emergence of viral resistance.

The results revealed at least one adverse event in majority of patients treated with fostemsavir and 17 deaths associated with progression of the disease by the database lock at week 24.